Docosahexaenoic acid trials in cystic fibrosis: A review of the rationale behind the clinical trials

Journal of Cystic Fibrosis

Volumn 4, Issue 1, 2005, Pages 27-34

  Van Biervliet, Stephanie ^a   Van Biervliet, J P ^a   Robberecht, E ^a   Christophe, A ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Cystic fibrosis; Docosahexaenoic acid; Inflammation; Omega 3 fatty acids

Indexed keywords

ACETYLSALICYLIC ACID; ARACHIDONATE 12 LIPOXYGENASE; ARACHIDONATE 15 LIPOXYGENASE; ARACHIDONIC ACID; BRADYKININ; CYCLOOXYGENASE 2; CYTOCHROME P450; DOCOSAHEXAENOIC ACID; ESSENTIAL FATTY ACID; GLYCEROPHOSPHOLIPID; GUANINE NUCLEOTIDE BINDING PROTEIN; IBUPROFEN; ICOSANOID; INTERLEUKIN 10; INTERLEUKIN 6; LEUKOTRIENE; LINOLEIC ACID; LINOLEOYL COENZYME A DESATURASE; LIPOXIN; MEMBRANE PHOSPHOLIPID; MONOUNSATURATED FATTY ACID; PHOSPHOLIPASE A2; POLYUNSATURATED FATTY ACID; PROSTACYCLIN; PROSTAGLANDIN; PROTEIN KINASE C; THROMBOXANE A2; THROMBOXANE B2; TRANSMEMBRANE CONDUCTANCE REGULATOR; UNINDEXED DRUG;

ANTIINFLAMMATORY ACTIVITY; CLINICAL TRIAL; CYSTIC FIBROSIS; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; DISEASE CONTROL; DRUG ACETYLATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME SUBSTRATE; ESSENTIAL FATTY ACID DEFICIENCY; FATTY ACID METABOLISM; HORMONE ACTION; HUMAN; LIPID HYDROLYSIS; LUNG FUNCTION; NONHUMAN; PATHOPHYSIOLOGY; PROSTAGLANDIN SYNTHESIS; REVIEW;

CLINICAL TRIALS; CYSTIC FIBROSIS; DOCOSAHEXAENOIC ACIDS; HUMANS;

EID: 14844303299     PISSN: 15691993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcf.2004.11.001     Document Type: Review

References (90)

1. S.C. Hyde P. Emsley M.J. Hartshorn M.M. Mimmack U. Gileadi S.R. Pearce, et al. Structural model of ATP-binding proteins associated with cystic fibrosis, multidrug resistance and bacterial transport Nature 346 1990 362-365
2. S.D. Freedman M.H. Katz E.M. Parker M. Laposata M.Y. Urman J.G. Alvarez A membrane lipid imbalance plays a role in the phenotypic expression of cystic fibrosis in CFTR -/- mice Proc. Natl. Acad. Sci. 96 1999 13995-14000
3. C.D. Stubbs A.D. Smith Essential fatty acids in membrane: Physical properties and function Biochem. Soc. Trans. 18 1990 779-781
4. S.D. Clarke D.B. Jump Dietary polyunsaturated fatty acid regulation of gene transcription Annu. Rev. Nutr. 14 1994 83-98
5. S.D. Clarke D.B. Jump Regulation of gene transcription by polyunsaturated fatty acids Prog. Lipid Res. 32 1993 139-149
6. R. Graber C. Sumida E.A. Nunez Fatty acids and cell signal transduction J. Lipid Mediat. 9 1994 91-116
7. E.A. Dennis The growing phospholipase A2 superfamily of signal transduction enzymes Trends Biochem. Sci. 22 1997 1-2
8. R.M. Kramer C. Hession B. Johansen G. Hayes P. McGray E.P. Chow, et al. Structure and properties of a human non-pancreatic phospholipase A2 J. Biol. Chem. 264 1989 5768-5775
9. M.V. Winstead J. Balsinde E.A. Dennis Calcium-independent phospholipase A2: Structure and function Biochim. Biophys. Acta 1488 2000 28-39
10. J.J. Seilhamer W. Pruzanski P. Vadas S. Plant J.A. Miller J. Kloss, et al. Cloning and recombinant expression of phospholipase A2 present in rheumatoid arthritic synovial fluid J. Biol. Chem. 264 1989 5335-5338
11. Y. Nakazoto M.S. Simonson W.H. Herman M. Konieczkowski J.R. Sedor Interleukin-1 alpha stimulates prostaglandin biosynthesis in serum-activated mesangial cells by induction of a non-pancreatic (type II) phospholipase A2 J. Biol. Chem. 266 1991 14119-14127
12. M. Murakami I. Kudo K. Inoue Molecular nature of phospholipases A2 involved in prostaglandin I2 synthesis in human umbilical vein endothelial cells. Possible participation of cytosolic and extracellular type II phospholipases A2 J. Biol. Chem. 268 1993 839-844
13. M. Murakami S. Shimbara T. Kambe H. Kuwata M.V. Winstead J.A. Tischfield, et al. The functions of five distinct mammalian phospholipase A2S in regulating arachidonic acid release. Type IIA and Type V secretory phospholipase A2S are functionally redundant and act in concert with cytosolic phospholipase A2 J. Biol. Chem. 273 1998 14411-14423
14. T. Hirabayashi T. Shimizu Localisation and regulation of cytosolic phospholipase A(2) Biochim. Biophys. Acta 1488 2000 124-138
15. C.C. Leslie Properties and regulation of cytosolic phospholipase A2 J. Biol. Chem. 272 1997 16709-16712
16. M.W. Konstan P.J. Byard C.L. Hoppel P.B. Davis Effect of high dose ibuprofen in patients with cystic fibrosis N. Engl. J. Med. 331 1995 848-854
17. W.L. Smith Prostanoid biosynthesis and mechanisms of action Am. J. Physiol. 263 1992 F181-F191
18. R.A. Coleman W.L. Smith S. Narumiya Classification of prostanoid receptors: Properties, distribution and structure of the receptors and their subtypes Pharmacol. Rev. 46 1994 205-229
19. E. Tuleja F. Mejza A. Cmiel A. Szczeklik Effects of cyclooxygenases inhibitors on vasoactive prostanoids and thrombin generation at the site of microvascular injury in healthy men Arterioscler. Thromb. Vasc. Biol. 23 2003 1111-1115
20. B. Strandvik E. Svensson H.W. Seyberth Prostanoid biosynthesis in patients with cystic fibrosis Prostaglandins Leukot. Essent. Fatty Acids 55 1996 419-425
21. R.J. Stead M.A. Barradas D.P. Mikhailidis J.Y. Jeremy M.E. Hodson J.C. Batten, et al. Platelet hyperaggregability in cystic fibrosis Prostaglandins Leukot. Med. 26 1987 91-103
22. X. Norel L. Walch J.P. Gascard V.d.V. Montpreville C. Brink Prostacyclin release and receptor activation: Differential control of human pulmonary venous and arterial tone Br. J. Pharmacol. 2004 (Jun 1) [Electronic publication]
23. E. Mayatepek G.F. Hoffmann B. Carlsson A. Larsson K. Becker Impaired synthesis of lipoxygenase products in glutathione synthetase deficiency Pediatr. Res. 35 1994 307-310
24. E. Mayatepek G.F. Hoffmann Leukotrienes: Biosynthesis, metabolism and pathophysiologic significance Pediatr. Res. 37 1995 1-9
25. J.T. Zakrzewski N.C. Barnes P.J. Piper J.F. Costello Detection of sputum eicosanoids in cystic fibrosis and normal saliva by bioassay and radioimmunoassay Br. J. Clin. Pharmacol. 1 1987 19-27
26. S. Schmitt-Grohe O. Eickmeier R. Shubert C. Bez S. Zielen Anti-inflammatory effects of montelukast in mild cystic fibrosis Ann. Allergy Asthma Immunol. 89 2002 599-605
27. C.N. Serhan N. Chiang Novel endogenous small molecules as checkpoint controllers in inflammation and resolution: Entree for resoleomics Rheum. Dis. Clin. North Am. 30 2004 69-95
28. C.L. Karp L.M. Flick K.W. Park S. Softic T.M. Greer R. Keledjian, et al. Defective lipoxin-mediated anti-inflammatory activity in the cystic fibrosis airway Nat. Immunol. 5 2004 388-392
29. F.A. Fitzpatrick R.C. Murphy Cytochrome P450 metabolism of arachidonic acid: Formation and biological actions of epoxygenase eicosanoids Pharmacol. Rev. 40 1988 229-241
30. B.E. Daikh J.M. Lasker J.L. Raney D.R. Koop Regio- and stereoselective epoxidation by human cytochromes P450 2C8 and 2C9 J. Pharmacol. Exp. Ther. 271 1994 1423-1427
31. M.L. Schwartzman J.C. McGiff Renal cytochrome P450 metabolism of arachidonic acid: Biochemistry and molecular biology In: S. Yamamoto W.L. Smith editors. Molecular biology of the arachidonate cascade 1995 Elsevier Amsterdam 229-242
32. I. Fleming Cytochrome P450 and vascular homeostasis Circ. Res. 89 2001 753-762
33. M.M. Dooper B. van Riel Y.M. Graus L. M'Rabet Dihomo-gamma-linolenic acid inhibits tumour necrosis factor-alpha production by human leucocytes independently of cyclooxygenase activity Immunology 110 2003 348-357
34. A. Christophe E. Robberecht H. Franckx F. De Baets M. van de Pas Effect of administration of gamma-linolenic acid on the fatty acid composition of serum phospholipids and cholesteryl esters in patients with cystic fibrosis Ann. Nutr. Metab. 38 1994 40-47
35. D. Schwarz P. Kisselev S.S. Ericksen G.D. Szklarz A. Chernogolov H. Honeck, et al. Arachidonic and eicosapentaenoic acid metabolism by human CYP1A1: Highly stereoselective formation of 17(R), 18(S)-epoxyeicosatetraenoic acid Biochem. Pharmacol. 67 2004 1445-1457
36. S. Hong K. Gronert P.R. Devchand R.L. Moussignac C.N. Serhan Novel docosatrienes and 17S-resolvins generated from docosahexaenoic acid in murine brain, human blood and glial cells. Autacoids in anti-inflammation J. Biol. Chem. 278 2003 14677-14687
37. C.N. Serhan C.B. Clish J. Brannon S.P. Colgan N. Chiang K. Gronert Novel functional sets of lipid-derived mediators with antiinflammatory actions generated from omega-3 fatty acids via cyclooxygenase 2-nonsteroidal anti-inflammatory drugs and transcellular processing J. Exp. Med. 192 2000 1197-1204
38. C.N. Serhan S. Hong K. Gronert S.P. Colgan P.R. Devchand G. Mirick, et al. Resolvins: A family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals J. Exp. Med. 196 2002 1025-1037
39. P.M. Farrell E.H. Mischler M.J. Engle J. Brown S.M. Lau Fatty acid abnormalities in cystic fibrosis Pediatr. Res. 19 1985 104-109
40. P.G. Robinson Essential fatty acids in cystic fibrosis Lancet 8 1975 919
41. V. Rogiers I. Dab R. Crokaert H.L. Vis Long chain non-esterified fatty acid pattern in plasma of cystic fibrosis patients and their parents Pediatr. Res. 1980 1088-1091
42. J.A. Dodge D.G. Salter J.G. Yassa Essential fatty acid deficiency due to artificial diet in cystic fibrosis Br. Med. J. 11 1975 192-193
43. R.A. Gibson J.K. Teubner K. Haines D.M. Cooper G.P. Davidson Relationships between pulmonary function and plasma fatty acid levels in cystic fibrosis patients J. Pediatr. Gastroenterol. Nutr. 5 1986 408-415
44. A. Christophe E. Robberecht Current knowledge on fatty acids in cystic fibrosis Prostaglandins Leukot. Essent. Fatty Acids 55 1996 129-138
45. J.D. Lloyd-Still S.B. Johnson R.T. Holmart Essential fatty acid status in cystic fibrosis and the effects of safflower oil supplementation Am. J. Clin. Nutr. 34 1981 1-7
46. G.L. Darmstadt J. McGuire V.A. Ziboh Malnutrition-associated rash of cystic fibrosis Pediatr. Dermatol. 17 2000 337-347
47. S.D. Freedman P.G. Blanco M.M. Zaman J.C. Shea M. Ollero I.K. Hopper, et al. Association of cystic fibrosis with abnormalities in fatty acid metabolism N. Engl. J. Med. 350 2004 560-569
48. B. Strandvik E. Gronowitz F. Enlund T. Martinsson J. Wahlstörm Essential fatty acid deficiency in relation to genotype in patients with cystic fibrosis J. Pediatr. 139 2001 650-655
49. tm1HGU/tm1HGU cystic fibrosis mouse Pediatr. Res. 53 2003 447-454
50. A. Christophe E. Robberecht F. De Baets H. Franckx Increase of long chain omega-3 fatty acids in the major serum lipid classes of patients with cystic fibrosis Ann. Nutr. Metab. 36 1992 304-312
51. W.R. Henderson Jr. S.J. Astley M.M. McCready P. Kushmerick S. Casey J.W. Becker, et al. Oral absorption of omega-3 fatty acids in patients with cystic fibrosis who have pancreatic insufficiency and in healthy control subjects J. Pediatr. 124 1994 400-408
52. J. Lloyd-Still C.A. Powers D.R. Hoffman K. Boyd-Trull L.A. Lester D.C. Benisek, et al. A randomised, controlled study examining the bioavailability and safety of algal docosahexaenoic acid (DHA) triacylglycerol in cystic fibrosis (CF) patients Pediatr. Pulmonol. S27 2004 331
53. M. Roulet P. Frascardo M. Pilet Essential fatty acid deficiency in well nourished young cystic fibrosis patients Eur. J. Pediatr. 156 1997 952-956
54. M.M. Ulane J.B. Butler A. Peri L. Miele R.E. Ulane V.S. Hubbard Cystic fibrosis and phosphatidylcholine biosynthesis Clin. Chim. Acta 230 1994 109-116
55. F.N. Bhura-Bandali M. Suh S.F.P. Man M.T. Clandinin The F508 mutation in the cystic fibrosis transmembrane conductance regulator alters control of essential fatty acid utilization in epithelial cells J. Nutr. 130 2000 2870-2875
56. J. Carlstedt-Duke M. Brönnegard B. Strandvik Pathological regulation of arachidonic acid release in cystic fibrosis: The putative basic defect Proc. Natl. Acad. Sci. U. S. A. 83 1986 9202-9206
57. V. Rogiers I. Dab Y. Michotte A. Vercruysse R. Crockaert H.L. Vis Abnormal fatty acid turnover in the phospholipids of the red blood cell membranes of cystic fibrosis patients (in vitro study) Pediatr. Res. 18 1984 704-709
58. R. Levistre M. Lemnaouar T. Rybkine G. Bereziat J. Masliah Increase of bradykinin stimulated arachidonic acid release in a delta-F508 cystic fibrosis epithelial cell line Biochim. Biophys. Acta 1181 1993 233-239
59. 2+ induced arachidonic acid release by epithelial cells DNA Cell Biol. 16 1997 749-759
60. J.P. Cosgrove D.F. Church W.A. Pryor The kinetics of the autooxidation of PUFA Lipids 22 1987 299-304
61. L.G. Wood D.A. Fitzgerald P.G. Gibson D.M. Cooper M.L. Garg Increased plasma fatty acid concentrations after respiratory exacerbations are associated with elevated oxidative stress in cystic fibrosis patients Am. J. Clin. Nutr. 75 2002 668-675
62. L.G. Wood D.A. Fitzgerald A.K. Lee M.L. Garg Improved antioxidant and fatty acid status of patients with cystic fibrosis after antioxidant supplementation is linked to improved lung function Am. J. Clin. Nutr. 77 2003 150-159
63. S. Loft E.B. Thorling H.E. Poulsen High fat diet induced oxidative DNA damage estimated by 8-oxo-7,8-dihydro-2-deoxyguanosine excretion in rats Free Radic. Res. 29 1998 595-600
64. 2 by bradykinin in human cystic fibrosis cell lines Am. J. Respir. Cell Mol. Biol. 17 1997 481-490
65. T.B. Harper H.P. Chase J. Henson P.M. Henson Essential fatty acid deficiency in the rabbit as a model of nutritional impairment in cystic fibrosis: In vitro and in vivo effects on lung defence mechanisms Am. Rev. Respir. Dis. 126 1982 540-547
66. A. Maqbool J. Shall B. Zemel B. Strandvik S.A. Virginia Essential fatty acid status and growth and pulmonary function in children with cystic fibrosis Pediatr. Pulmonol. S27 2004 337
67. P. Chase J. Dupont Abnormal levels of prostaglandins and fatty acids in blood of children with cystic fibrosis Lancet 29 1978 236-238
68. B. Rigas J.R. Korenberg W.W. Merill L. Levine Prostaglandins E2 and F2alfa are elevated in saliva of cystic fibrosis patients Am. J. Gastroenterol. 84 1989 1408-1412
69. G.E. Carpagnano P.J. Barnes P.J. Geddes M.E. Hodson S.A. Kharitonov Increased leukotriene B4 and interleukin-6 in exhaled breath condensate in cystic fibrosis Am. J. Respir. Crit. Care Med. 167 2003 1109-1112
70. P. Greally M.J. Hussein A.J. Cook A.P. Sampson P.J. Piper J.F. Price Sputum tumor necrosis factor alpha and leukotriene concentrations in cystic fibrosis Arch. Dis. Child. 68 1993 389-392
71. M.W. Konstan R.W. Walenga J.B. Hillard Leukotriene B4 markedly elevated in the epithelial lining fluid of patients with cystic fibrosis Am. Rev. Respir. Dis. 148 1993 896-901
72. M.W. Konstan M. Berger Current understanding of the inflammatory process in cystic fibrosis Pediatr. Pulmonol. 24 1997 137-142
73. T.Z. Khan J.S. Wagener T. Bost J. Martinez F.J. Accurso D.W. Riches Early pulmonary inflammation in infants with cystic fibrosis Am. J. Respir. Crit. Care Med. 151 1995 1075-1082
74. D.S. Armstrong K. Grimwood R. Carzino J.B. Carlin A. Olinsky P.D. Phelan Lower respiratory infection and inflammation in infants with newly diagnosed cystic fibrosis BMJ 310 1995 1571-1572
75. V. Raia L. Maiuri G. de Ritis B. de Vizia L. Vacca R. Conte, et al. Evidence of chronic inflammation in morphologically normal small intestine of cystic fibrosis patients Pediatr. Res. 47 2000 344-350
76. U. Keicher B. Koletsko D. Reinhardt Omega-3 fatty acids suppress the enhanced production of 5-lipoxygenase products from polymorph neutrophil granulocytes in cystic fibrosis Eur. J. Clin. Invest. 25 1995 915-919
77. P. Linsdell Inhibition of cystic fibrosis transmembrane conductance regulator chloride channel currents by arachidonic acid Can. J. Physiol. Pharmacol. 78 2000 490-499
78. M.D. Carattino W.G. Hill T.R. Kleyman Arachidonic acid regulates surface expression of epithelial sodium channels J. Biol. Chem. 278 2003 36202-36213
79. J.D. Morrow J.A. Awad H.J. Boss I.A. Blair L.J. Roberts Non-cyclooxygenase-derived prostanoids (F2-isoprostanes) are formed in situ on phospholipids Proc. Natl. Acad. Sci. U. S. A. 89 1992 10721-10725
80. J. Rokach S.P. Khanapure S.W. Hwang M.J. Adiyaman A. Lawson G.A. FitzGerald The isoprostanes: A perspective Prostaglandins 54 1997 823-851
81. C.E. Collins P. Quaggiotto L. Wood E.V. O'Loughlin R.L. Henry M.L. Garg Elevated plasma levels of F2 alpha isoprostane in cystic fibrosis Lipids 34 1999 551-556
82. E.A. Cowley Isoprostane-mediated secretion from human airway epithelial cells Mol. Pharmacol. 64 2003 298-307
83. M. Gronn E. Christensen T.A. Hagve B.O. Christophersen Effects of dietary purified eicosapentaenoic acid (20:5(n-3)) and docosahexaenoic acid (22:6(n-3)) on fatty acid desaturation and oxidation in isolated rat liver cells Biochim. Biophys. Acta 1125 1992 35-43
84. R.S. Chapkin M.Y. Hong Y.Y. Fan L.A. Davidson L.M. Sanders C.E. Henderson, et al. Dietary n-3 PUFA alter colonocyte mitochondrial membrane composition and function Lipids 37 2002 193-199
85. E.J. Corey C. Shih J.R. Cashman Docosahexaenoic acid is a strong inhibitor of prostaglandin but not leukotriene biosynthesis Proc. Natl. Acad. Sci. U. S. A. 80 1983 3581-3584
86. - secretion J. Surg. Res. 110 2003 338-343
87. B. De Visia V. Raia C. Spano C. Pavlidis A. Coruzzo M. Alessio Effect of an 8-month treatment with ω-3 fatty acids (eicosapentaenoic acid and docosahexaenoic acid) in patients with cystic fibrosis J. Parenter. Enteral. Nutr. 27 2003 52-57
88. A. Christophe E. Robberecht Directed modification instead of normalisation of fatty acid patterns in cystic fibrosis: An emerging concept Curr. Opin. Clin. Nutr. Metab. Care 4 2001 111-113
89. R. Lawrence T. Sorell Eicosapentaenoic acid in cystic fibrosis: Evidence of a pathogenetic role for leukotriene B4 Lancet 342 1993 465-469
90. N. Beckles Willson T.M. Elliot M.L. Everard Omega-3 fatty acids (from fish oils) for cystic fibrosis Cochrane Library 2 2003